European Heart Journal Advance Access originally published online on May 26, 2006
European Heart Journal 2006 27(24):3018-3026; doi:10.1093/eurheartj/ehl015
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
1 Department of Cardiology, University Hospital Maastricht, Maastricht, The Netherlands
2 Department of Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy
3 Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK
4 Department of Cardiology, University Hospital Lund, Lund, Sweden
5 Department of Clinical Epidemiology and Medical Technology Assessment, University Hospital Maastricht, Maastricht, The Netherlands
6 Department of Cardiology, Hospital Universitario Gregorio Maranon, Madrid, Spain
7 Cardiology Department, University Hospital of Heraklion, Heraklion, Crete, Greece
8 Department of Cardiology, University Hospital Nancy, Nancy, France
9 Department of Cardiology, San Filippo Neri Hospital, Rome, Italy
Received 9 January 2006; revised 7 April 2006; accepted 13 April 2006; online publish-ahead-of-print 26 May 2006.
* Corresponding author. Tel: +31 43 3875350; fax: +31 43 3875104. E-mail address: r.nieuwlaat{at}cardio.azm.nl
Aims To describe guideline adherence and application of different stroke risk stratification schemes regarding antithrombotic therapy in real-life atrial fibrillation (AF) patients and to assess which factors influence antithrombotic management decisions.
Methods and results The Euro Heart Survey enrolled 5333 AF patients in 35 countries, in 2003 and 2004. Prescription of antithrombotic drugs, especially oral anticoagulation (OAC), was hardly tailored to the patient's stroke risk profile as indicated by the joint guidelines of the American College of Cardiology, American Heart Association, and the European Society of Cardiology, ACCP guidelines, or CHADS2 and Framingham risk scores. In multivariable analysis, only a limited number of the well-known stroke risk factors triggered OAC prescription. In contrast, less relevant factors, of which clinical type of AF and availability of an OAC monitoring outpatient clinic were the most marked, played a significant role in OAC prescription. Electrical cardioversions and catheter ablations clearly triggered OAC prescription, whereas pharmacological cardioversions even in the presence of stroke risk factors did not.
Conclusion Antithrombotic therapy in AF is hardly tailored to the patient's stroke risk profile. Factors other than well-known stroke risk factors were significantly involved in antithrombotic management decisions. To facilitate this tailored treatment, guideline writers and physician educators should focus on providing one uniform and easy to use stroke risk stratification scheme.
Key Words: Atrial fibrillation • Stroke • Antithrombotic therapy • Oral anticoagulation • Guidelines • Risk stratification
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Camm The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin Eur. Heart J., November 1, 2009; 30(21): 2554 - 2555. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leclercq, L. Padeletti, R. Cihak, P. Ritter, G. Milasinovic, D. Gras, V. Paul, I.C. Van Gelder, C. Stellbrink, G. Rieger, et al. Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics Europace, October 28, 2009; (2009) eup318v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Connolly, H. J.G.M. Crijns, C. Torp-Pedersen, M. van Eickels, C. Gaudin, R. L. Page, S. H. Hohnloser, and for the ATHENA Investigators Analysis of Stroke in ATHENA: A Placebo-Controlled, Double-Blind, Parallel-Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter Circulation, September 29, 2009; 120(13): 1174 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pisters, T. Dinh, H. J. Crijns, D. Chua, M. Legal, S. J. Shalansky, T. Richard, F. Butaffuoco, M. Vanhaeverbeek, L. B. Goldstein, et al. Clopidogrel plus aspirin in atrial fibrillation. N. Engl. J. Med., September 24, 2009; 361(13): 1312 - 1313. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat, L. W. Eurlings, J. G. Cleland, S. M. Cobbe, P. E. Vardas, A. Capucci, J. L. Lopez-Sendon, J. G. Meeder, Y. M. Pinto, and H. J.G.M. Crijns Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1690 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C McKenna, S Palmer, M Rodgers, D Chambers, N Hawkins, S Golder, S Van Hout, C Pepper, D Todd, and N Woolacott Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom Heart, April 1, 2009; 95(7): 542 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pisters, R. Nieuwlaat, C. B. de Vos, and H. J. Crijns Comprehensive upstream treatment for atrial fibrillation, when and how? Europace, April 1, 2009; 11(4): 397 - 399. [Full Text] [PDF]
|
|
|
|
|
|
R. Nieuwlaat and S. J Connolly Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes Heart, January 15, 2009; 95(2): 95 - 97. [Full Text] [PDF]
|
|
|
|
|
|
D. W.J. Dippel and M. L. Simoons Improving Adherence to Guidelines for Acute Stroke Management Circulation, January 6, 2009; 119(1): 16 - 18. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Hohnloser, G. Z. Duray, U. Baber, and J. L. Halperin Prevention of stroke in patients with atrial fibrillation: current strategies and future directions Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H4 - H10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aliot and J. N. Ruskin Controversies in ablation of atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H32 - H54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Meiltz, M. Zimmermann, P. Urban, A. Bloch, and on behalf of the Association of Cardiologists of t Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace, June 1, 2008; 10(6): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 2008; 39(6): 1901 - 1910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nieuwlaat, M. H. Prins, J.-Y. Le Heuzey, P. E. Vardas, E. Aliot, M. Santini, S. M. Cobbe, J. W.M.G. Widdershoven, L. H. Baur, S. Levy, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation Eur. Heart J., May 1, 2008; 29(9): 1181 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nieuwlaat, T. Dinh, S. B. Olsson, A. J. Camm, A. Capucci, R. G. Tieleman, G. Y.H. Lip, H. J.G.M. Crijns, and on behalf of the Euro Heart Survey Investigators Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur. Heart J., April 1, 2008; 29(7): 915 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" Circulation, February 5, 2008; 117(5): e150 - e150. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lane and G. Y.H. Lip Barriers to Anticoagulation in Patients With Atrial Fibrillation: Changing Physician-Related Factors Stroke, January 1, 2008; 39(1): 7 - 9. [Full Text] [PDF]
|
|
|
|
|
|
R. Nieuwlaat, L. W. Eurlings, A. Capucci, and H. J.G.M. Crijns Atrial fibrillation in the 'real world': undecided issues Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I122 - I128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]
|
|